
GeneDx Investors Face August Deadline in Securities Fraud Lawsuit
Investors who purchased GeneDx Holdings Corp. common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek lead plaintiff status in a newly filed securities fraud class action lawsuit currently pending in the United States District Court for the District of Connecticut.























